Kura Oncology Receives $55 Million Under Oberland Capital Agreement

Kura Oncology said Nov. 10 it received $55 million at closing under a financing agreement with affiliates of Oberland Capital and plans to begin a registrational study of darlifarnib in the first half of 2027. The planned trial will target about 40 patients with HRAS-mutant salivary gland cancer.

The agreement provides up to $300 million in potential funding, subject to conditions, including as much as $275 million in debt and $25 million in equity investments. At closing, Kura received $50 million in debt before fees and a $5 million equity investment. Further funding is available through company-option and milestone-based tranches; another tranche requires mutual agreement.

Kura said it reached alignment with the U.S. Food and Drug Administration (FDA) on the study design. The single-arm monotherapy trial is expected to enroll about 40 patients. Kura expects the financing to support the KOMZIFTI commercial launch, continued investment in ziftomenib development, and darlifarnib monotherapy registrational and combination studies.